[VIDEO] Imagion Biosystems (ASX:IBX) finds that diagnostic tech has potential to work on multiple cancers, page-59

Two reasons. Firstly it would be rejected by shareholders and secondly no one will launch a takeover until the technology is proven to work. Most likely occur after the success of the second larger trial. If you listen to all the interviews Bob clearly outlines that from the first trial we already know the technology is safe and works, they just need enough of a dataset to officially confirm this. They are also using what they learn from this trial to fine tune the perfect dosage for the second trial. It will take a significant amount of money to bring the technology to market at scale so of course any takeover attempt is unlikely to happen until the success of the larger trial. Big business is more averse to risk than retail. This has been outlined many times here and is really just common sense.